Clover Biopharmaceuticals, Inc.

95 articles about Clover Biopharmaceuticals, Inc.

• Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients

  2/10/2020

  Clover Biopharmaceuticals announced that it has successfully produced its trimeric Spike-protein subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system.

• Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)

  1/28/2020

  Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has initiated development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus that is believed to have originated from Wuhan, China.

• 

  Clinical Catch-Up: December 30, 2019 – January 2, 2020

  1/6/2020

  Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.

• Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China

  12/30/2019

  The Phase III, multi-center trial in China is designed to assess the efficacy, safety and pharmacokinetics of SCB-808 and originator drug Enbrel® in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) via subcutaneous administration.

• Clover Biopharmaceuticals Completes $43 Million Series B Financing

  11/28/2019

  Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced the completion of a US$ 43 million Series B financing.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)

  11/21/2019

  Clover Biopharmaceuticals announced that the first patient was dosed in a Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in Australia for the treatment of cancer patients with malignant pleural effusions.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites

  9/29/2019

  Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the treatment of cancer patients with malignant ascites.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis

  9/10/2019

  The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of intraperitoneally administered SCB-313 as a single-agent for the treatment of peritoneal carcinomatosis.

• Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases

  7/10/2019

  Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases

• Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

  5/7/2019

  A phase I clinical trial for malignant ascites is planned to initiate in China this year.

• Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in China

  8/1/2018

  SCB-808 is a proposed biosimilar of Enbrel® (etanercept) being developed in the prefilled syringe formulation for the treatment of rheumatoid arthritis and other autoimmune diseases.

• Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites

  6/18/2018

  Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, for the treatment of cancer patients with malignant ascites.

• Clover Using GE FlexFactory for China Biologic Manufacturing Plant

  1/25/2018

  Clover Biopharma announced plans to build a biologic drug manufacturing facility in Changxing, Zhejiang Province.

• Clover Biopharmaceuticals Receives CFDA Approval to Initiate Clinical Trials in China with Etanercept Biosimilar Candidate SCB-808

  12/22/2017

  A phase I clinical trial is planned to initiate in China in mid-2018.

• Clover Bio of Chengdu Completes $9.5M Series A for Biotech/Biosimilar Portfolio

  12/15/2017

  Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5M Series A financing led by Tianhe Life Sciences Venture Fund.